Tech Company Financing Transactions
Reprieve Cardiovascular Funding Round
On 2/20/2024, Reprieve Cardiovascular raised $42 million in Series A funding from Lightstone Ventures, Sante Ventures and Arboretum Ventures.
Transaction Overview
Company Name
Announced On
2/20/2024
Transaction Type
Venture Equity
Amount
$42,000,000
Round
Series A
Investors
Lightstone Ventures (Lead Investor)
Sante Ventures (Lead Investor)
Proceeds Purpose
The funding will advance the Company's clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
459 Fortune Blvd.
Milford, MA 01757
USA
Milford, MA 01757
USA
Phone
Website
Email Address
Overview
Reprieve Cardiovascular is a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF). The company's Reprieve technology is being investigated as an innovative fluid management therapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Alexander Martin
Chief Executive Officer
James Dillon
Chief Medical Officer
Howard Levin
Chief Technical Officer
Andrew Halpert
VP - Bus. Development
Gregory Mann
VP - Operations
Kenneth Luppi
Browse more venture capital transactions:
Prev: 2/20/2024: Bioptimus venture capital transaction
Next: 2/20/2024: Trace Genomics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs